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Abstract
Diagnosis of pulmonary arterial hypertension (PAH) is difficult due to the lack of specific clin-
ical symptoms and biomarkers, especially at early stages. We compared plasma metabolic
fingerprints of PAH patients (n = 20) with matched healthy volunteers (n = 20) using, for the
first time, untargeted multiplatform metabolomics approach consisting of high-performance
liquid and gas chromatography coupled with mass spectrometry. Multivariate statistical
analyses were performed to select metabolites that contribute most to groups’ classification
(21 from liquid in both ionization modes and 9 from gas chromatography-mass spectrome-
try). We found metabolites related to energy imbalance, such as glycolysis-derived metabo-
lites, as well as metabolites involved in fatty acid, lipid and amino acid metabolism. We
observed statistically significant changes in threitol and aminomalonic acid in PAH patients,
which could provide new biochemical insights into the pathogenesis of the disease. The
results were externally validated on independent case and control cohorts, confirming up to
16 metabolites as statistically significant in the validation study. Multiplatform metabolo-
mics, followed by multivariate chemometric data analysis has a huge potential for explaining
pathogenesis of PAH and for searching potential and new more specific and less invasive
markers of the disease.
Introduction
Pulmonary arterial hypertension (PAH) is a heterogeneous disease with multifactorial patho-
physiology. PAH is currently classified into various clinical phenotypes, but they all share their
severity and progressiveness as common features. The lack of specific clinical symptoms, espe-
cially at early stages hinders the diagnosis [1]. PAH, when not diagnosed, can lead to right
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ventricle failure and consequently to premature death. Additionally, pathomechanisms of PAH
remain still not fully understood. Knowledge regarding pathological hallmarks of PAH, such as
cell proliferation, apoptosis resistance, vascular remodelling, vasoconstriction and increased
angiogenesis, derives mainly from experimental animal models [2,3]. For this reason, new, sen-
sitive and specific markers of PAH in humans are needed to better understand the pathological
processes of the disease and consequently improve current diagnosis and treatment. Metabolo-
mics focuses on qualitative and quantitative analysis of low-molecular-weight compounds
(metabolites) in various biological samples (plasma/serum, urine, saliva, tissue, exhaled breath)
to understand the complex and dynamic responses of living systems to diverse stimuli, such as
pathological processes, drug treatments, genetic variability or environmental factors [4,5]. The
metabolome, as a final consequence of derangements in genome and proteome is considered to
be a link in the genotype-to-phenotype gap. In the area of PAH research, we consider that the
application of metabolomics can be a potential tool for understanding its pathogenesis and to
find new diagnostic markers. Only a few reports can be found in the literature suggesting the
role of metabolic alterations, such as: excessive cellular glucose uptake, glycolytic metabolism,
high-density lipoprotein cholesterol and insulin resistance in PAH pathogenesis [6]. One of
the most recent studies employed a metabolomics approach to determine metabolic profiles of
lung tissue derived from patients with severe PAH [7]. Obviously, analysis of tissue samples
provides detection of site-specific metabolite alterations that might be characteristic for disease
stage. However, its application in diagnosis and clinical practice is limited due to its invasive-
ness, while plasma analysis could provide diagnostic markers more readily available to
clinicians.
In order to search for potential markers of pathological conditions occurring in PAH, untar-
geted multiplatform metabolomics, using high-performance liquid and gas chromatography
coupled with mass spectrometry (LC-MS and GC-MS), was applied to plasma samples of PAH
patients and healthy controls, providing data on the plasma metabolic fingerprint of PAH.
Materials and Methods
Study design and samples
This case-control study included 20 patients with confirmed PAH derived from Hospital Clinic
in Barcelona and 20 healthy controls. Plasma samples were collected at fasting condition at the
same time of the day into EDTA tubes and frozen at -80°C for aproximately 6 months, until
metabolomic analysis. The studied groups were matched according to age (p = 0.96), body
mass index (p = 0.87) and sex (p = 0.62). Independent recruitment of other additional 20
patients and 12 controls processed in a separated batch and not used in the main analyses
allowed external validation. The investigation was carried out in accordance with approval of
The ethical committee of clinical investigations in Barcelona (CEIC, the approval number
CIF-G-08431173) and the informed consent was signed by each participant of the study. The
detailed characteristics of study and validation cohorts are described in S1 and S2 Tables.
Plasma was separated from fasting blood samples for metabolic fingerprinting. Metabolomics
included liquid chromatography-mass spectrometry (LC-MS) in positive and negative modes
and gas chromatography-mass spectrometry (GC-MS).
Plasma metabolic fingerprinting with HPLC-ESI-QTOF-MS and
GC-EI-Q-MS
Sample preparation for LC-MS included deproteinization, centrifugation and filtration. Quality
control samples (QCs) were prepared as aliquots of a pool of equal volumes from all samples
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included in the study, using the same preparation procedures. Samples were analysed by an
HPLC system connected to a Q-TOF LC-MS detector. Randomized samples were analysed in
two separate runs (for positive and negative modes). Sample preparation for GC-MS involved
deproteinization, centrifugation, supernatant’s evaporation and two-step derivatization
employing methoxymation and silylation. GC−MS analysis was performed with a gas chro-
matograph interfaced to an inert quadrupole analyser.
Data extraction and treatment
For LC-MS, raw datasets were extracted by the Molecular Feature Extraction tool in the Mas-
sHunter Qualitative Analysis software (Agilent Technologies). For GC-MS, deconvolution and
data processing were performed with Automated Mass Spectrometry Deconvolution and Iden-
tification System (www.amdis.net). Due to retention time shifts during both LC−MS and
GC-MS sequence runs, samples were multi-aligned using Mass Profiler Professional (Agilent
Technologies). Subsequently, data filtration regarding quality assurance criteria (QA) and fre-
quency in at least one of the compared groups (i.e., in 90% of samples) was applied.
Statistical analysis and metabolite identification
Principal component analysis (PCA) was applied to check quality of the analysis, trends in the
datasets and detect potential outliers. Then, multivariate statistics were used to select com-
pounds with statistically significant differences between the groups. To select metabolites con-
tributing the most into groups’ discrimination, orthogonal partial least squares discriminant
analysis (OPLS-DA) was applied. Statistically significant metabolites were selected based on
the Jack-knife confidence interval (p<0.05) and variable importance into projection (VIP) val-
ues. Compounds detected by LC-MS were first putatively identified using public available data-
bases. The identity of compounds found in the databases was confirmed by LC−MS/MS
analyses. For GC-MS, metabolites found to be statistically significant were identified based on
comparison of their retention time, retention index and mass spectra with Fiehn RTL library,
in-house target plasma library or NIST library.
A detailed description of analytical and statistical methods can be found in S1 File.
Results
Quality of the analysis
The obtained raw datasets, after alignment step, consisted of 27362, 12360 and 139 features for
LC-ESI(+)-MS, LC-ESI(-)-MS and GC-MS, respectively. Data was initially filtered according to
quality assurance criteria before performing PCA analysis. LC-MS, in positive and negative
ionization modes, and GC-MS data matrices contained 1950, 1114 and 49 variables, respec-
tively. QCs clustered adequately (Fig 1), confirming that the system was stable during analyses
and that the differences between compared groups reflected true biological differences, and not
artefacts derived from analytical variability. The Hottelling’s test was applied during PCAmod-
els’ construction to reveal potential outliers. In PCAmodel built on GC-MS dataset, one analyt-
ical outlier, which resulted to be a control sample, was detected and subsequently excluded
from further statistical analysis of GC-MS data.
Sample discrimination and metabolite identification
Before OPLS-DA, variables were further filtered based on minimum frequency in the study
groups (required presence in at least 90% of samples in PAH or C group), 836, 637 and 40 vari-
ables remained for LC-MS in positive ionization mode, LC-MS in negative ionization mode,
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Fig 1. PCAmodels built with the data after filtration step. (A) Scores plot for a PCAmodel built with the data set obtained in LC−MS positive mode.
Quality parameters for the model: explained variance R2 = 0.468, predicted variance Q2 = 0.227. (B) Scores plot for a PCAmodel built with the data set
obtained in LC−MS negative mode. R2 = 0.427, Q2 = 0.139. (C) Scores plot for a PCAmodel built with the data set obtained in GC−MS. R2 = 0.567, Q2 =
0.193. QCs have been marked as black diamonds. Pulmonary hypertensive group (PAH) and control (C) have been marked as red triangles and green
circles, respectively. PCA: principal component analysis; LC-MS: liquid chromatography-mass spectrometry; GC-MS: gas chromatography-mass
spectrometry; QCs: quality control samples.
doi:10.1371/journal.pone.0160505.g001
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and GC-MS, respectively. OPLS-DA models (Fig 2) clearly separated the PAH and control
groups in the 3 modalities. The quality of the OPLS-DA models was provided by explained var-
iance R2 (0.982 for LC-MS positive ionization, 0.998 for LC-MS negative ionization, and 0.825
for GC−MS) and predicted variance Q2 (0.524 for LC-MS positive ionization, 0.502 for LC-MS
negative ionization, and 0.649 for GC−MS). The results of metabolite identification that repre-
sented statistically significant differences between PAH and C group are presented in Tables 1
and 2. To select metabolites which contribute the most into groups’ discrimination, Jack-knife
confidence intervals (p<0.05) and VIP values were checked (VIP>1). The compounds num-
bered 149, 63 and 9 were selected as statistically significant for LC-ESI(+)-MS, LC-ESI(-)-MS
and GC-MS, respectively.
To avoid over-fitting and check the predictive value of the obtained OPLS-DA models, the
leave-one-third-out cross-validation method was applied with the use of Matlab 2013b soft-
ware. The percentages of samples that were correctly classified by each OPLS-DA model were
calculated as the average of all prediction steps, which were 83% ± 12%, 92% ± 8%, and 83% ±
14% for LC−MS positive mode, LC−MS negative mode, and GC−MS, respectively. The root
mean squares errors of cross-validation (RMSECV) were 0.3233, 0.2873 and 0.3277 for LC
−MS positive mode, LC−MS negative mode, and GC−MS, respectively.
Each metabolite was externally validated by univariate statistical comparisons in an inde-
pendent case and control study using multiple correction methods and performed in the vali-
dation study (Table 3).
Discussion
In this study we identify, for the first time, systemic metabolic differences in plasma in PAH
patients with respect to controls using a multimodality metabolomics approach. The metabo-
lites identified are associated with various metabolic pathways including glycolysis, pentose
phosphate pathway (PPP), lipid and fatty acid metabolism, amino acid metabolism, tricarboxi-
lic acid (TCA) cycle and urea cycle. Interestingly, we found other metabolites not previously
associated with PAH (i.e., threitol, aminomalonic acid) that may explain particular features of
PAH and also could be used as biomarkers of the disease.
Lactate was markedly elevated in PAH patients, suggesting a shift in glucose metabolism
towards glycolysis for ATP production at the expense of oxidative phosphorylation, the “so-
called” Warburg effect. This shift provides a rapid route for ATP generation and prevents
excessive mitochondrial reactive oxygen species production [8]. Although this metabolic
switch is well established in rapidly proliferating endothelial and smooth muscle cells during
the vascular remodelling of pulmonary hypertension [9], a recent report by Zhao’s et al. has
shown reduced glycolysis in human PAH lung compared to normal tissue [7]. This discrepancy
might be explained because Zhao’s et al. used lung samples with severe PAH rather than sam-
ples of patients with less severe PAH, which is the case of previous reports and our own study.
Also, the analysis of lung biopsies (local metabolome) instead of blood plasma (whole-body
metabolome) may partly explain this difference. Other metabolites related to carbohydrate
metabolism, predominantly threitol, were increased in the PAH group. Threitol is an end prod-
uct of xylose metabolism that is connected to the PPP through the glucuronate pathway [10].
The levels of threitol and other polyols are altered in diseases associated with carbohydrate
metabolism derangements such as diabetes mellitus [11]. Together, these results suggest a
deregulated carbohydrate metabolism in PAH patients, where the intermediates produced by
the high glycolytic rate could feed the PPP for the production of nucleotides, amino acids and
nicotinamide adenine dinucleotide phosphate (NADPH) needed to support the increased bio-
synthetic demands during cell proliferation, similarly to cancer [12].
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Fig 2. OPLS-DA plots for plasmametabolic fingerprints obtained from C and PAH groups. (A) OPLS-DAmodel (R2 = 0.844, Q2 = 0.653) for LC-MS
data in positive ionization mode. (B) OPLS-DAmodel (R2 = 0.897, Q2 = 0.618) for LC-MS data in negative ionization mode. (C) OPLS-DAmodel (R2 = 0.825,
Q2 = 0.649) for GC-MS data. Pulmonary hypertensive group (PAH) and control (C) have been marked as red triangles and green circles, respectively.
OPLS-DA: orthogonal partial least squares discriminant analysis.
doi:10.1371/journal.pone.0160505.g002
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The disrupted energy production is also connected to alterations in lipid and fatty acid
metabolism. We found increased levels of free fatty acids, in particular nonanoic acid, and glyc-
erol in the plasma of PAH patients, suggesting enhanced lipolysis. During starvation/exercise,
glycerol and free fatty acids are released from adipose tissue (lipolysis) for energy generation.
Free fatty acids are used as respiratory fuel by the tissues and glycerol is taken into hepatocytes
for gluconeogenesis. In a healthy situation, insulin prevents lipolysis and inhibits hepatic gluco-
neogenesis, but not in diabetes or in the metabolic syndrome [13]. In addition, we observed a
significant increase of long-chain fatty acylcarnitines in the PAH group. Long-chain acylcarni-
tines facilitate the transfer of long-chain fatty acids from cytoplasm into mitochondria during
fatty acid β-oxidation (FAO). Acylcarnitines accumulate and are released into the circulation
due to FAO defects [14] and can also be reflective of incomplete long-chain FAO, as it occurs
Table 1. Identified metabolites that significantly change in human plasma from PAH patients vs. Control group, detected in LC-MS.
Name RT
(min)
Ionization Mono-
isotopic
mass
VIP % Change
vs. control
CV
QCs
[%]
Identiﬁcation p
valueJK
FC
Nonanoic acid 12.7 positive 158.1304 1.0 28 9 159.1375, 141.9564,124.9622,
97.9679, 89.0596, 43.0545
0.0027 1.28
Eicosenoic acid 34.1 negative 310.2842 1.8 27 8 Database, isotopic distribution 0.0094 1.27
Azelaic acid 1.5 negative 188.1043 2.2 48 12 Database, isotopic distribution 0.0241 1.48
Octadecadienal 27.3 positive 264.2451 1.4 -22 9 Database, isotopic distribution 0.0113 0.78
Palmitoylcarnitine 18.1 positive 399.3347 1.5 31 5 400.3418, 341.2682, 85.0285, 60.0809 0.0027 1.31
Stearoylcarnitine 21.2 positive 427.3653 1.3 31 4 428.3725, 311.2927, 85.0281, 60.0799 0.0036 1.31
Dimethylnonanoylcarnitine 8.7 positive 329.2564 1.1 -21 10 329.2568, 271.1880, 85.0284, 60.0796 0.0114 0.79
Palmitamide 26.5 positive 255.2579 3.0 -18 7 256.2644, 102.0911, 116.1065,
88.0756, 57.0701
0.0154 0.82
Oleamide 27.3 positive 281.2741 1.2 -14 7 281.2735, 265.2529, 247.2420,
135.1166, 97.1010, 83.0856, 69.0701,
57.0702
0.0015 0.86
Stearamide 31.1 positive 283.2889 1.6 -21 12 284.2962, 116.1072, 102.0911,
88.0756, 57.0699
0.0031 0.79
Palmitoleamide 23.3 positive 253.2410 1.1 -25 8 Database, isotopic distribution 0.0081 0.75
Sphingosine 21.7 positive 311.2823 3.2 -42 12 Database, isotopic distribution 0.0214 0.58
Glycochenodeoxycholate
sulphate
8.5 negative 529.2697 1.8 84 9 528.2620, 448.3069, 74.0236 0.0131 1.84
Glycochenodeoxycholate 11.7 negative 449.3134 1.2 66 11 Database, isotopic distribution 0.0065 1.66
Deoxycholic acid-3
glucuronide
8.1 negative 568.3228 1.5 63 9 567.3152, 505.3094, 391.2780,
113.0218, 85.0277, 75.0089, 44.9971
0.0244 1.63
Hydroxy-oxo-cholanoic acid 34.1 positive 390.2779 1.2 40 27 391.2852, 167.0361, 149.0225,
71.0851, 57.0703
0.0038 1.40
Glutamine 1.1 negative 146.0693 1.0 59 6 145.0615, 127.0500, 109.0396,
58.0316, 41.9997
0.0088 1.59
Tryptophan 1.1 positive 204.0897 2.5 -14 8 205.0984, 188.0706, 146.0599,
118.0651
0.0123 0.86
Uric acid 0.7 negative 168.0262 1.2 20 3 167.0195, 124.0147, 96.0198, 69.0089,
41.9990
0.0088 1.20
LPC 9.6 positive 511.3277 1.1 70 29 512.3277, 184.0726, 104.1070,
86.0963
0.0028 1.70
PC(26:1) 24.1 positive 647.4436 1.2 -29 26 648.4489, 184.0727, 104.1054,
86.0951
0.0034 0.71
Abbreviations: RT-retention time, VIP-variable importance to projection, CV QCs-coefﬁcient of variation in QC samples, JK-Jack-knife conﬁdence interval
level, FC-fold-change
doi:10.1371/journal.pone.0160505.t001
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Table 2. Identified metabolites that significantly change in human plasma from PAH patients vs. Control group, detected in GC-Q-MS.
Name T Q RT (min) RI VIP % Change vs. control CV QCs [%] p value JK FC
Lactic acid 117 191, 147, 73 6.7 733 1.4 123 10 0.0001 2.23
Pyruvic acid 174 89, 73, 59 6.6 721 1.0 71 19 0.0233 1.71
Threitol 73 147,217,103 12.9 1176 1.6 115 24 0.0065 2.15
Glycerol 205 147, 117, 73 9.8 945 0.9 175 14 0.0132 2.75
Cholesterol 129 329,73,368 27.6 2826 1.1 -9 27 0.0072 0.91
Urea 147 189, 73,66 9.4 923 1.0 39 17 0.0035 1.39
Creatinine 115 73,100,329 13.5 1232 1.3 77 29 0.0063 1.77
Aminomalonic acid 218 73,147,320 12.5 889 1.1 84 28 0.0113 1.84
Isoleucine/Norleucine 86 75,69, 188 8.4 853 1.5 -21 24 0.0022 0.79
Abbreviations: T-target ion, Q-qualiﬁer ions, RI-retention index, CV QCs-coefﬁcient of variation in QC samples, JK-Jack-knife conﬁdence interval level, FC-
fold-change
doi:10.1371/journal.pone.0160505.t002
Table 3. Results of univariate statistical analysis in the independent validation study.
Metabolite p-value p-value FDR
Lactic acid 0.001 0.010
Pyruvic acid 0.096 0.108
Threitol 0.001 0.016
Glycerol 0.035 0.044
Cholesterol 0.003 0.017
Urea 0.011 0.033
Creatinine 0.016 0.024
Aminomalonic acid 0.011 0.024
Isoleucine/norleucine 0.953 0.953
Nonanoic acid 0.998 0.998
Eicosenoic acid 0.674 0.787
Azelaic acid 0.889 0.889
Octadecadienal 0.137 0.187
Palmitoylcarnitine 0.023 0.031
Stearoylcarnitine 0.027 0.039
Palmitamide 0.029 0.047
Oleamide 0.021 0.041
Stearamide 0.020 0.044
Palmitoleamide 0.127 0.188
Sphingosine 0.046 0.093
Glycochenodeoxycholate sulphate 0.029 0.036
Glycochenodeoxycholate 0.370 0.648
Deoxycholic acid-3 glucuronide 0.034 0.039
Hydroxy-oxo-cholanoic acid 0.309 0.332
Glutamine 0.032 0.036
Tryptophan 0.024 0.036
Uric acid 0.626 0.878
LPC 0.283 0.330
PC(26:1) 0.179 0.228
Abbreviations: FDR- False Discovery Rate
doi:10.1371/journal.pone.0160505.t003
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in type 2 diabetes and in insulin resistance [15]. The accumulation of even long-chain acylcar-
nitines of 18-carbons (stearoylcarnitine) and 16-carbons (palmitoylcarnitine) found here
points to an incomplete FAO, which might be associated with the impairment of the TCA
cycle known to occur in PAH [16]. Also, the alterations in the fatty acid metabolism might be
associated in part to an increase in the fatty acid ω-oxidation, as it has been shown to occur in
lungs from advanced PAH patients [7]. Activation of this pathway could help to alleviate the
failure of the fatty acid β-oxidation. Thus, as a consequence of the metabolic switch to cyto-
plasmic glycolysis, there is a marked reduction in the metabolism of pyruvate into the mito-
chondria, causing decreased energy production from oxidative phosphorylation and TCA
cycle. The reduction in TCA cycle capacity is likely to contribute to a more inefficient long-
chain FAO. Interestingly, it is becoming increasingly recognized that PAH patients exhibit fea-
tures of the metabolic syndrome and insulin resistance [17]. This could explain, at least in part,
some of the alterations in lipid and fatty acid metabolism and the deregulated carbohydrate
metabolism observed in PAH. Furthermore, these metabolic alterations might be related to the
hypoxemic state of the disease. Accordingly, our clinical data show mild arterial hypoxemia
(PaO2< 80 mmHg, see S1 and S2 Tables) in the PAH group, most likely due to the abnormal
pulmonary vascular remodelling that occurs in PAH. Under reduced oxygen availability, there
is increased expression of the hypoxia-inducible factor (HIF-1) in the affected tissues, as is the
case of human pulmonary artery endothelial [18] and smooth muscle cells [19]. As the master
regulator of the hypoxic response, HIF-1 up-regulates an array of enzymes that activate anaero-
bic glycolysis and suppress the oxidative phosphorylation and TCA cycle, playing a predomi-
nant role in PAH induction [8].
In addition to energy stores and structural components of cell membranes, lipids are impor-
tant components of the endocrine system producing bioactive substances that influence meta-
bolic and vascular homeostasis. We found a significant decrease in the levels of palmitamide,
stearamide and oleamide in the plasma of patients with PAH. These compounds are fatty acid
amides (FAAs), a large class of endogenous signalling lipids of growing interest. Through inter-
actions with cannabinoid, vanilloid and peroxisome proliferator-activated receptors (PPARs),
FAAs regulate a variety of pathophysiological functions such as appetite, lipid and glucose
metabolism, vasodilation, cardiac function and inflammation [20]. Many actions of FAAs are
potentially protective to the cardiovascular system. For instance, FAAs are potent regional
vasodilators [21]. FAAs also play a role in the regulation of energy metabolism by stimulating
lipolysis and fatty acid oxidation [22], and have potential anti-diabetic effects [23]. These
observations suggest that down-regulation of FAAs might contribute to some of the metabolic
derangements found in PAH.
Similarly, we found a significant decrease of sphingosine in the plasma of PAH patients.
Sphingosine is a potent bioactive signalling lipid involved in the regulation of processes such as
cell growth, differentiation, and apoptosis [24]. Like FAAs, sphingolipids have been suggested
to be agonists of PPARs [25], and therefore, alterations in the levels of sphingolipids might
have an impact on lipid metabolism, fatty acid oxidation and glucose homeostasis [26]. Of
note, a recent study has shown significant elevation of sphingosine-1-phosphate (S1P) in lung
tissues from patients with severe PAH [27]. S1P elevation was accompanied by increased
expression of sphingosine kinase 1 (SphK1), the predominant isoform responsible for the syn-
thesis of S1P from sphingosine in the lungs. Thus, the reduction of sphingosine found in our
study might be consequence of an increase in SphK1 and hence in the production of S1P, caus-
ing depletion of the substrate for S1P production (sphingosine). This interpretation will need
to be corroborated in future targeted studies covering different stages of disease severity.
Our study also demonstrates changes in cholesterol metabolism in PAH. While there was a
slight reduction in free cholesterol, we observed a substantial elevation of cholesterol-derived
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bile acids and some of their metabolites (glycochenodeoxycholate sulphate and deoxycholic
acid 3-glucuronide). Besides facilitating the absorption of dietary lipids and fat-soluble vita-
mins, bile acids regulate glucose homeostasis, lipid and lipoprotein metabolism, energy expen-
diture, and inflammation through interaction with nuclear receptors (farnesoid X, pregnane X,
vitamin D receptors) and with GPBAR1 (G protein-coupled bile acid receptor 1) [28]. Impor-
tantly, a recent study has shown elevation of bile acid metabolites in lung tissue from PAH
patients; the authors suggested that the de novo biosynthesis of bile acids was primarily local-
ized in pulmonary vascular endothelial cells [29]. These findings suggest a potential role for
bile acids in PAH pathogenesis and the need for further studies to evaluate this family of
metabolites as biomarkers of disease progression.
Other metabolites with significant changes in PAH comprise amino acids. Noteworthy, we
detected a substantial increase in circulating glutamine in the PAH group (59% vs. control).
Glutamine is the most abundant free amino acid in plasma and is utilized at high rates by rap-
idly dividing cells (glutaminolysis) [30]. Glutamine can be hydrolysed to glutamate and subse-
quently converted to α-ketoglutarate in the mitochondria. α-ketoglutarate can enter the TCA
cycle and replenish the metabolic intermediates (anaplerosis), thereby supporting the biosyn-
thetic demands for NADPH and fatty acids during rapid cell growth [30], as in cancer [12].
Importantly, a recent study has shown increased levels of plasmatic glutamine in a model of
monocrotaline-induced PAH [31].
On the other hand, tryptophan was decreased in the PAH group, which can be of relevance
for PAH pathogenesis. Tryptophan is converted to serotonin by the enzyme tryptophan
hydroxylase (coded in the gene TPH1). Serotonin has been suggested to enhance pulmonary
arterial smooth muscle cell proliferation, vasoconstriction and microthrombosis [32]. TPH1 is
mainly expressed in the gut and mediates the generation of serotonin in the periphery [33].
Interestingly, increased TPH1 expression has been reported in lungs and in pulmonary endo-
thelial cells from patients with idiopathic PAH [34]. Moreover, a study aimed to investigate the
effect of TPH1 deficiency on hypoxia-induced PAH in mice confirmed its crucial role in dis-
ease development [35]. In our study, the decrease in plasma tryptophan might be indicative of
its metabolic conversion into serotonin, which could enhance cell proliferation and vascular
remodelling in PAH. However, this suggestion needs to be confirmed in further studies assess-
ing the ratio tryptophan/serotonin and possible correlation with disease progression.
Interestingly, a substantial increase of aminomalonic acid was detected in the PAH group.
Although the origin of this metabolite in blood has not been well elucidated yet, aminomalonic
acid can be routinely detected in the serum metabolome of healthy individuals by GC-MS [36].
Aminomalonic was first identified in human atherosclerotic plaques [37], and later was associ-
ated with the presence of foam cells and macrophage-rich tissues in atherosclerotic rabbits
(aorta, blood, spleen, lungs) [38]. Besides, the origin of aminomalonic acid has been associated
with free-radical mediated oxidation of amino acid residues in proteins, mainly glycine and
cysteine [39]. Recently, increased plasma level of aminomalonic acid was observed in patients
with large aneurysms [40], suggesting a role for aminomalonic acid in cardiovascular diseases
with an inflammatory and/or oxidative stress component. Consistent with this, our clinical
data showed elevated levels of the inflammatory marker C-reactive protein in the PAH group
(PAH 0.65±0.73 vs. Control 0.22±0.28, p<0.001, see S1 and S2 Tables). Since increasing evi-
dence indicates that inflammation and oxidative stress play an important role in the patho-
physiology of PAH [41], aminomalonic acid emerges as a potential biomarker regarding the
inflammatory/oxidative extent. The connections between metabolic pathways altered in PAH
patients are presented in Fig 3 and in S2 File.
This study has some limitations, the most important one, the sample size. However, as the
first study applying this type of methodology, the reference values provided here can help
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Fig 3. The connections betweenmetabolic pathways altered in plasma of PAH patients as compared to control
group. TCA: tricarboxylic acid.
doi:10.1371/journal.pone.0160505.g003
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sizing future studies to explore particular aspects of the disease. On the other hand, due to the
extreme rarity of PAH in humans, accruing a large sample is difficult, time-consuming and
requires multicenter studies. Due to the small sample size, we could not stratify by time from
diagnosis or background therapy. Further studies on larger samples that can profit from the
use of quantitative targeted multiplatform metabolomics will be able to confirm the potential
markers identified in this study. Additionally, a joint analysis of the proposed metabolic mark-
ers together with clinical and hemodynamic parameters in PAH patients can provide further
advancements in clinical and diagnostic practices.
In summary, in this study, plasma untargeted multiplatform metabolomics followed by bio-
informatics data analysis provides data on diagnostic markers and pathophysiological mecha-
nisms occurring in PAH. Metabolites significantly changed in PAH patients as compared to
control were associated with glycolytic shift, lipid-related energy imbalance as well as cellular
signal transduction. These metabolic abnormalities could be considered as pathological hall-
marks of PAH. Finally, plasma metabolome includes the biochemical information from all
organs of the body. Based on clinical characteristics of participants (S1 and S2 Tables), there
are no clear symptoms and analytical changes that can be attributed to other different patholo-
gies. However, we cannot completely exclude that PAH affects in a very late stage the metabo-
lism of different organs from lung to heart. Further metabolic studies on specific organs, such
as liver or kidney, would clarify this concern.
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